Form 4 for EW Edwards Lifesciences
Accepted 2022-05-10 00:00:00 ET · period of report 2022-05-07 · accession 0001225208-22-006819 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2022-05-10 | 2022-05-07+ | EW | Zovighian Bernard J | CVP, TMTT | F - Tax | $100.52 | -7,470 | 40.6K | -16% | -$750.9K |
| D | 2022-05-10 | 2022-05-08 | EW | Zovighian Bernard J | CVP, TMTT | M - OptEx | $0.00 | +12.6K | 53.2K | +31% | $0 |
| D | 2022-05-10 | 2022-05-08 | EW | Zovighian Bernard J | CVP, TMTT | M - OptEx | $0.00 | -12.6K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-05-08 | F | D | 6,837 | $100.52 | 46,336 | D | — | — | |
| 2 | Common | Common Stock | 2022-05-08 | M | A | 12,600 | $0.00 | 53,173 | D | — | — | (F1) On May 8, 2019, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 2, 2022, the Compensation Committee of the Board of Directors determined that 175% of the target number of shares would vest as of May 8, 2022, and the actual number of shares vested are reflected on this Form 4. |
| 3 | Common | Common Stock | 2022-05-07 | F | D | 633 | $100.52 | 40,573 | D | — | — | |
| 4 | Derivative | Performance Rights | 2022-05-08 | M | D | 12,600 | $0.00 | 0 | D | $0.00 · 2022-05-08 to — | 12,600 Common Stock | (F1) On May 8, 2019, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 2, 2022, the Compensation Committee of the Board of Directors determined that 175% of the target number of shares would vest as of May 8, 2022, and the actual number of shares vested are reflected on this Form 4. |